Evidence map›Paper›PMID 26478203›Full record

ArticleVaccine2015

Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Nancy J Cox, Julian Hickling, Rebecca Jones, Guus F Rimmelzwaan, Linda C Lambert, John Boslego, Larisa Rudenko, Leena Yeolekar, James S Robertson, Joachim Hombach and 1 more

Open access · greenAbstract readConference Proceedings
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Influenza A virus vaccines for swine.Veterinary microbiology · 2017
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 5 countries.

Nancy J CoxInfluenza Division, National Center for Infectious Diseases, 1600 Clifton Road NE, Atlanta, GA 30333, United States.
Julian HicklingWorking in Tandem Ltd, Cambridge CB1 7AB, United Kingdom.
Rebecca JonesWorking in Tandem Ltd, Cambridge CB1 7AB, United Kingdom.
Guus F RimmelzwaanDepartment of Virology, Erasmus Medical Center, Dr Molewaterplein 50, Rotterdam CE 3015, The Netherlands.
Linda C LambertRespiratory Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID/NIH/DHHS, 5601 Fishers Lane, Bethesda, MD 20892, United States.
John BoslegoPATH, 445 Massachusetts Avenue, NW Suite 1000, Washington, DC 20001, United States.
Larisa RudenkoInstitute of Experimental Medicine, Russian Academy of Medical Sciences, 12 Acad. Pavlov Street, St Petersburg 197376, Russian Federation.
Leena YeolekarVaccine Production, Serum Institute of India, 212/2 Hadapsar, Pune, India.
James S RobertsonIndependent Consultant, St. Albans, United Kingdom.
Joachim HombachInitiative for Vaccine Research (IVR), Immunization, Vaccines and Biologicals (IVB), World Health Organization, Switzerland.
Justin R OrtizInitiative for Vaccine Research (IVR), Immunization, Vaccines and Biologicals (IVB), World Health Organization, Switzerland.
World Health Organization · CHErasmus University Rotterdam · NLInstitute of Experimental Medicine · RUNational Center for Infectious Diseases · USProgram for Appropriate Technology in Health · USSerum Institute of India (India) · INUnited States Department of Health and Human Services · US

Funding

NCEZID CDC HHS U50 CK000431World Health Organization 001
6 · The paper itself

Abstract

On 5-7 May 2014, the World Health Organization (WHO) convened the second integrated meeting on "influenza vaccines that induce broadly protective and long-lasting immune responses". Around 100 invited experts from academia, the vaccine industry, research and development funders, and regulatory and public health agencies attended the meeting. Areas covered included mechanisms of protection in natural influenza-virus infection and vaccine-induced immunity, new approaches to influenza-vaccine design and production, and novel routes of vaccine administration. A timely focus was on how this knowledge could be applied to both seasonal influenza and emerging viruses with pandemic potential such as influenza A (H7N9), currently circulating in China. Special attention was given to the development of possible universal influenza vaccines, given that the Global Vaccine Action Plan calls for at least one licensed universal influenza vaccine by 2020. This report highlights some of the topics discussed and provides an update on studies published since the report of the previous meeting.

Indexed as

Adjuvants, ImmunologicAnimalsClinical Trials as TopicCross ProtectionHumansInfluenza A Virus, H7N9 SubtypeInfluenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsPandemicsVaccinationVaccines, AttenuatedVaccines, InactivatedWorld Health OrganizationAdjuvants, ImmunologicInfluenza VaccinesVaccines, AttenuatedVaccines, InactivatedH7N9 vaccineInfluenzaPandemic influenza vaccineSeasonal influenza vaccineUniversal influenza vaccineVaccine

Identifiers

PMID26478203
PMCPMC8218335
OpenAlexW1900060674

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.